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Abstract 
Background: Zinc oxide nanoparticle (ZNP) has been applied in various biomedical fields. Here, we investigated the 
usage of ZNP as an antigen carrier for vaccine development by combining a high affinity peptide to ZNP.
Results: A novel zinc oxide‑binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (Ka = 2.26 × 106 M−1) was 
isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causa‑
tive agent of scrub typhus. The ZNP/ZBP‑ScaA complex was efficiently phagocytosed by a dendritic cell line, DC2.4, 
in vitro and significantly enhanced anti‑ScaA antibody responses in vivo compared to control groups. In addition, 
immunization with the ZNP/ZBP‑ScaA complex promoted the generation of IFN‑γ‑secreting T cells in an antigen‑
dependent manner. Finally, we observed that ZNP/ZBP‑ScaA immunization provided protective immunity against 
lethal challenge of O. tsutsugamushi, indicating that ZNP can be used as a potent adjuvant when complexed with 
ZBP‑conjugated antigen.
Conclusions: ZNPs possess good adjuvant potential as a vaccine carrier when combined with an antigen having a 
high affinity to ZNP. When complexed with ZBP‑ScaA antigen, ZNPs could induce strong antibody responses as well 
as protective immunity against lethal challenges of O. tsutsugamushi. Therefore, application of ZNPs combined with a 
specific soluble antigen could be a promising strategy as a novel vaccine carrier system.
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Background
Biocompatible-nanomaterials exert an immunomodu-
latory effect on the immune system and engineered 
nanoparticles have been considered as promising adju-
vants and/or carrier systems for vaccine development 
against infections and cancers [1, 2]. Zinc oxide (ZnO) 
nanoparticles (ZNPs), due to their good biocompatibility 
and low cost, have been widely applied as food ingredi-
ents, UV-blocking agents, and anti-microbial materials 
[3–5]. In addition, ZNPs possess promising potential for 
biomedical applications, such as bio-imaging and drug 
delivery [6]. In order to expand the applicability of ZNPs, 
diverse approaches have been used to explore the prop-
erties of peptides that enable binding to the surface of 
inorganic materials [7–9] and several types of peptides 
with high affinity to ZNPs have been identified [10–14]. 
Unlike covalently bound linker surface modifications, 
peptides bound to nanomaterials utilize high affinity 
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non-covalent bonds, which simplify the process for func-
tionalization of ZNPs.
Recent studies have reported that immune cells and 
organs are the primary sites for the deposition of inor-
ganic NPs after systemic exposure, and NPs mediate 
inflammatory or immunomodulatory effects on innate 
and adaptive immune cells [15]. Our recent study in 
which mice were subcutaneously injected with iron oxide 
(Fe3O4)–zinc oxide (ZnO) core–shell nanoparticles also 
resulted in foreign body responses in the form of mac-
rophage infiltration, but otherwise did not show any 
systemic distribution or toxicity at up to 200  mg  kg−1 
[16]. Nevertheless, ZNPs exposure might induce strong 
local inflammation at the injection site [17] and this can 
be linked to the generation of antigen-specific adap-
tive immune responses, including antibodies as well as 
T cell responses, when combined with a specific protein 
antigen [18]. Even though the detailed immunological 
mechanisms of how ZNPs stimulate the immune system 
and contribute to the generation of specific immunity 
against co-injected antigen need to be investigated [19], 
it is intriguing to observe that inflammatory responses 
induced by injection of ZNPs are linked to augmentation 
of antigen-specific adaptive immunity.
In order to investigate the potential applicability of 
ZNPs as a vaccine adjuvant and carrier system for infec-
tious diseases, we selected scrub typhus, caused by Ori-
entia tsutsugamushi infection, as a model disease. Scrub 
typhus is one of the main causes of acute febrile illness 
in the Asian-Pacific region [20, 21] and the rate of inci-
dence has been estimated to be one million cases annu-
ally [22]. During the last decade, the incidence of scrub 
typhus has also rapidly increased in South Korea [23] 
and China [24]. In addition, sporadic outbreaks of scrub 
typhus in several countries in the endemic region make it 
a serious public health issue [25, 26]. Clinical symptoms 
of the mite-borne disease include eschar at the site of 
mite biting, lymphadenopathy, fever, headache, myalgia, 
and rash. Due to the lack of specificity of its early clini-
cal presentation, delayed treatment with proper antibiot-
ics, such as doxycycline or chloramphenicol, often leads 
to more severe organ failures, including acute respiratory 
distress, meningoencephalitis, gastrointestinal bleeding, 
acute renal failure, hypotensive shock, and coagulopa-
thy [22]. However, an effective vaccine has not yet been 
developed despite continuous efforts in the last several 
decades [22]. While a major outer membrane protein, 
TSA56, has been studied as a conventional target for 
scrub typhus vaccine since it is an immunodominant 
antigen, many issues remain that need to be resolved for 
the development of an effective vaccine, especially for 
cross-protective immunity against diverse genotypes [22, 
27]. Previously, our group reported the potential role of 
the ScaA protein, an autotransporter protein of O. tsut-
sugamushi, in bacterial pathogenesis and evaluated the 
immunogenicity of ScaA for protective immunity against 
lethal O. tsutsugamushi infection in mice, suggesting that 
ScaA should be considered as a novel target for scrub 
typhus vaccine [28, 29]. ScaA functions as a bacterial 
adhesion factor, and anti-ScaA antibody significantly 
neutralizes bacterial infection of host cells. In addition, 
immunization with ScaA not only provides protective 
immunity against lethal challenges with the homologous 
strain, but also confers significant protection against het-
erologous strains when combined with TSA56 [28].
In the present study, we screened and selected a high 
affinity ZBP and investigated whether ZBP conjugation 
with the bacterial antigen, ScaA, could further enhance 
the generation of adaptive immunity when complexed 
with ZNPs, by measuring antigen-specific humoral 
immunity as well as T cell responses. In addition, we also 
tested if ZNP/ZBP-ScaA complexes can provide pro-
tective immunity against lethal infections in  vivo. Our 
results showed that immunization with ZNP/ZBP-ScaA 
complexes induced proper adaptive immune responses 
and could provide comparable protection against lethal 
challenges of O. tsutsugamushi as a conventional vac-
cine adjuvant, alum hydroxide, suggesting that ZNPs may 
potentially be used as an antigen carrier and adjuvant 
system when combined with ZBP-conjugated antigens.
Results
Preparation of ZnO nanoparticles
The morphologies and particle sizes of the prepared 
ZNPs were observed by transmission electron micros-
copy (TEM) (Fig.  1a). ZNPs are almost spherically 
shaped. The size of ZNPs shows a Gaussian distribu-
tion and the nanoparticles have an average diameter 
and standard deviation of 5.48 ± 0.75 nm (Fig. 1b). The 
photoluminescence spectra of ZNPs under the excitation 
wavelength of 330 nm showed a major peak at ~380 nm, 
the expected emission of the ZnO bandgap (3.3  eV), as 
well as additional broad visible emissions with a peak at 
470 nm (Fig. 1c), which were related to surface and defect 
emissions [30].
Selection of novel ZnO‑binding peptides
To make use of ZNP as an antigen carrier, we first 
screened ZBPs from a random 8-mer peptide library 
and examined their affinity to ZNP. After three rounds 
of screening, the amino acid sequences of selected ZBPs 
were determined by mass spectrometry and the detec-
tion frequencies of amino acids in each position (P1–P4) 
from amino terminals are presented in Fig.  2a. Based 
on the detection frequency data, we synthesized eight 
peptide candidates for further assays to determine their 
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affinity to ZNP. The synthesized peptides consisted of 
selected amino acids and a linker (GGDA) to allow for 
flexibility (Table 1) [2]. The relative affinity of the selected 
peptides to ZNPs was compared by measuring fluores-
cent intensity at 488  nm after binding assays using the 
FITC-labelled peptides. As shown in Fig.  2b, two pep-
tides with sequences of FPYPGGDA and FPYDGGDA 
exhibited the highest affinity to ZnO nanoparticles 
among the eight peptides examined. The binding affinity 
of the ZBP, FPYDGGDA, to ZNP as determined by iso-
thermal titration calorimetry (Fig. 2c), showed a Ka value 
of 2.26  ×  106  M−1. This is stronger than a previously 
reported peptide, RPHRKGGDA (Ka =  6.9 ×  105  M−1) 
[2], and comparable to that of EAHVMHKVAPRP 
(Ka ≤ 5.9 × 106 M−1) [14]. The binding constant of this 
novel ZBP is comparable to those of strong inorganic 
binders, which have Ka values ranging from 1 ×  104 to 
1 × 108 M−1 [2, 31]. To further enhance the binding affin-
ity of the peptide to ZnO, we generated a triplicate tan-
dem repeat of the peptide (3×  ZBP) [2]. This 3×  ZBP 
showed enhanced binding to ZNP compared to the 
1× ZBP (Fig. 3a). The binding of each peptide was satu-
rated at ~16 nmol for 1× ZBP and ~32 nmol for 3× ZBP 
with 50 μg of ZNPs, resulting in 0.32–0.64 nmol of pep-
tide binding per 1 μg of nanoparticle. Next, we generated 
ScaA antigen [28] fused with 3×  ZBP for scrub typhus 
vaccine study. As expected, addition of 3×  ZBP to the 
recombinant protein enhanced the binding of ScaA to 
ZNPs by  ~2.5 fold over that of ScaA without 3×  ZBP 
(Fig. 3b).
In order to investigate potential changes in colloidal 
properties of ZNPs upon the protein binding in aque-
ous solutions [32], the hydrodynamic diameters and 
zeta potential values for ZNPs were measured. As seen 
in Table  2, the hydrodynamic diameters of ZNPs were 
increased in aqueous solutions, especially in phosphate-
buffered solution containing NaCl (150 mM), when com-
pared to that in ethanol. The ionic solution shields the 
surface charge and may cause agglomeration [32]. Nev-
ertheless, it is interesting to note that surface binding of 
ZBP-ScaA (isoelectric point  =  6.57) on ZNPs stabilize 
the hydrodynamic diameters of ZNPs and reduced the 
negative charges. Surface coating of ZNPs with the pro-
tein antigen may reduce agglomeration and negative zeta 
potential, which may also enhance the cellular uptake of 
the complexes.
Finally, we examined the intracellular delivery of ZNP 
coated with 3× ZBP labelled with FITC or 3× ZBP-ScaA 
conjugate. Consistent with our previous study [2], the 
peptides and protein antigen immobilized on ZNPs were 
efficiently delivered into the cytoplasm of DC2.4 cells and 
formed aggregates that primarily co-localized with lys-
osomes (Fig.  3c, d), indicating that ZNP complexes are 
internalized through phagocytosis [2].
Protective immune responses against O. tsutsugamushi 
infection
Since systemic exposure to ZNPs complexed with oval-
bumin (OVA) antigen could enhance antigen-specific 
immune responses including OVA-specific antibod-
ies and T cells [18], we measured humoral immune 
responses in mice immunized with ScaA antigen immo-
bilized on ZNPs. At 1 week after primary and secondary 
immunization, ScaA-specific antibodies were examined. 
As seen in Fig.  4a, remarkable increases of anti-ScaA 
Fig. 1 Characterization of ZnO nanoparticle (ZNP). a TEM images 
of the monodispered spherical ZNPs. b Gaussian size distribution 
of ZNPs. c Photoluminescence spectrum of ZNPs showing UV and 
visible emissions
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IgG1 and IgG2C antibodies in the sera were observed 
in mice immunized with ZNP/ZBP-ScaA compared 
with ZNP or ZBP-ScaA-treated mice. It is also nota-
ble that the antibody responses of the ZNP/ZBP-ScaA 
mice group were significantly higher than those of the 
ZNP/ScaA group, suggesting that enhanced binding of 
ZBP-ScaA to ZNPs via ZBP could further increase anti-
gen-specific humoral immunity. In addition, the levels 
of ScaA-specific antibodies in the ZNP/ZBP-ScaA mice 
group were comparable to those of mice immunized 
with a conventional adjuvant, Alum (Alum/ZBP-ScaA). 
To investigate whether immunization of ZNP/ZBP-
ScaA complexes can also induce cell-mediated immu-
nity, we examined T cells responses by measuring their 
production of IFN-γ in an antigen-dependent manner 
(Fig.  4b, c). The frequencies of IFN-γ-secreting CD4+ 
or CD8+ T cells in spleens of NP/ZBP-ScaA-immunized 
mice significantly increased by approximately six or 
four fold, respectively, when compared with the non-
immunized group (ZNP). In contrast, CD4+ or CD8+ 
T cells from spleens of other control groups (ZBP-ScaA 
or ZNP/ScaA) did not show significant IFN-γ secretion 
upon antigenic stimulation. Only marginal increases 
(about 2 fold) in IFN-γ+ production by CD4+ T cells 
from the ZNP/ScaA group were detected. Even though 
Fig. 2 Screening and characterization of high affinity ZNP‑binding peptide. a Amino acid sequences at the indicated positions (P1–P4) of peptides 
bound to ZNP were determined by mass spectrometry. b Relative affinities of selected peptides labeled with FITC were assessed by measuring 
fluorescent intensity of ZNP‑peptide complexes. Error bars mean ± SD. c Detection of the interaction of a ZBP, FPYDGGDA, with ZNP by isothermal 
titration calorimetry (ITC)
Table 1 Amino acid sequences of synthesized ZBPs
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the relative frequencies of IFN-γ-secreting CD4+ or 
CD8+ T cell responses in ZNP/ZBP-ScaA-immunized 
mice is lower than those of the Alum/ZBP-ScaA group, 
these results clearly show that immunization of ZNP/
ZBP-ScaA can induce antigen-specific T cell immunity 
as well as humoral responses in  vivo. To expand these 
findings, we examined levels of signature cytokines for 
type 1 (IFN-γ and IL-2) and type 2 T cell responses (IL-
10) in the culture media of splenocytes from immunized 
mice after stimulation with ScaA antigen (Fig. 5). Sub-
stantial production of type 1 cytokines (IFN- and IL-2) 
from the splenocytes in an antigen dependent manner 
was consistently observed in the immunized groups 
where ZNP or Alum was used as adjuvant. In addition, 
secretion of type 2 cytokine, IL-10, was relatively lower 
in the splenocytes from mice immunized with ZNP/
ZBP-ScaA than other immunization groups, suggesting 
an immune bias toward TH1 responses by ZNP/ZBP-
ScaA immunization.
Fig. 3 Complex formation of ZNP/ZBP and its delivery into DCs. a Relative affinity of 1× ZBP and 3× ZBP is assessed by measuring fluorescent 
intensity of ZNP‑peptide complex. 50 μg of ZNPs were incubated with indicated amount of peptide and the fluorescent intensities of the complex 
were measured after washing with PBS. b Gel electrophoresis data showing the relative fraction of ZNP‑bound (P, pellet) or unbound (S, super‑
natant) ScaA after incubation with ZNPs and ScaA with or without 3× ZBP fusion. Relative intensity of the protein bands (P and S) was indicated 
below. c Intracellular delivery of ZNP/ZBP complex into DCs was assessed by fluorescence confocal microscopy after incubation of DC2.4 cells 
with ZNP and 3× ZBP‑FITC complex. Lysosomes (red) were stained with LysoTracker. d Intracellular delivery of ZNP/ZBP‑ScaA complex into DCs 
was assessed by fluorescence confocal microscopy after incubation of DC2.4 cells with ZNP and 3xZBP‑ScaA complex. ScaA antigens (green) and 
Lysosomes (red) were stained with anti‑ScaA antibody and LysoTracker, respectively. Intracellular co‑localization of ZNP/ZBP‑ScaA complexes with 
lysosomes were assessed by confocal imaging of z‑stacks and orthogonal views (yz and xz) were shown in left and bottom panels. DIC differential 
interference contrast. White bar 10 μm
Table 2 Characterization of  hydrodynamic diameters and   
zeta potentials of ZNPs
Samples (solvent) Hydrodynamic  
diameter (nm)
Zeta (mV)
ZNP (EtOH) 75.18 13.6
ZNP (H2O) 200.3 −29.8
ZNP/ZBP (H2O) 232.6 −29.4
ZNP/ZBP‑ScaA (H2O) 280.2 −19.8
ZNP (PBS) 460.1 −24.4
ZNP/ZBP (PBS) 552.1 −22.7
ZNP/ZBP‑ScaA (PBS) 295.2 −12.7
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Finally, the protective effect of ZNP/ZBP-ScaA immu-
nization against O. tsutsugamushi infection was investi-
gated in vivo by challenging mice with 100 × LD50 of O. 
tsutsugamushi at 1 week after the third immunization. As 
shown in Fig.  6, a significant level of protection against 
bacterial challenge was observed in the ZNP/ZBP-
ScaA-immunized group as well as in Alum/ZBP-ScaA-
immunized mice. In contrast, there was no significant 
protection in mice immunized with either ZNP/ScaA or 
ZBP-ScaA alone. Therefore, administration of ZBP-ScaA 
complexed with NP could provide protective immunity 
against O. tsutsugamushi infection as efficiently as an 
adjuvant-based immunization (Alum/ZBP-ScaA).
Discussion
Soluble peptide and protein antigens alone are generally 
weak immunogens due to their inefficient delivery into 
antigen-presenting cells (APCs) and low immune-stim-
ulatory nature. Particulation of a soluble antigen could 
facilitate antigen delivery into APCs, such as dendritic 
cells and macrophages, and enhance its immunogenic-
ity. Costimulatory signals also need to be concomitantly 
Fig. 4 Induction of ScaA specific immune responses. a Antibody responses observed in the immunized mice. Mice were immunized with ZNP, 
ZBP‑ScaA, ZNP/ScaA, NP/ZBP‑ScaA, or Alum/ZBP‑ScaA (n = 3/group) twice and the levels of anti‑ScaA IgG1 and IgG2C in the sera were measured by 
ELISA at 1 week after immunization. Antibody titer was assessed up to 102,400. b IFN‑γ‑positive CD4+ or CD8+ T cells in splenocytes stimulated with 
ScaA antigen were detected at 1 week after second immunization as in a. Representative dot blots obtained by FACS analysis were presented.  
c Average percentile of three independent experiments for IFN‑γ‑positive CD4+ or CD8+ T cells in splenocytes from immunized mice were pre‑
sented. Error bars mean ± SD
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induced when antigens are delivered into APCs in order 
to generate effective adaptive immune responses. In this 
study, we examined ZNP as a vaccine adjuvant by utiliz-
ing a ZBP for the particulation of a soluble antigen. We 
also investigated whether enhanced affinity of an antigen 
to ZNPs can induce stronger adaptive immunity when 
delivered as a complex.
First, we exploited physical properties of NPs which 
can selectively absorb proteins on their surfaces [33], 
thereby forming particulated forms of soluble antigens. 
Previously, metal oxide nanoparticles including ZNP were 
shown to bind multiple plasma proteins such as albumin, 
immunolglobulin, and fibrinogen [34]. The binding con-
stant (Ka) of albumin to naïve or polyethyleneimine-mod-
ified ZNP ranges from 2.6 × 104 to 7.9 × 104 M−1 [35]. A 
novel ZBP screened in this study showed almost a hun-
dred times enhanced affinity (Ka = 2.3 × 106 M−1) to ZNP 
when compared to that of serum albumin, and its affinity 
can be further increased by using tandem repeats of the 
ZBP sequence (Figs. 2, 3). Previously, we showed that con-
jugation of a tumor antigen with a high affinity ZBP could 
significantly enhance intracellular delivery of the antigen 
into dendritic cells after complex formation with Fe3O4–
ZnO core–shell nanoparticles [2]. These complexes 
were primarily delivered into lysosomal compartments 
where the antigens can be processed for presentation by 
APCs to T cells. Intracellular delivery of ZBP-ScaA anti-
gens complexed with ZNPs into the lysosomal compart-
ments of a dendritic cell line was also confirmed in this 
study (Fig.  2c). Since the novel ZBP sequence (FPYDG-
GDA) selected in this study showed even stronger bind-
ing to ZNPs when compared to a previous ZBP sequence 
(RPHRKGGDA), we could expect more efficient delivery 
of the ZBP conjugated antigens into APCs when com-
plexed with ZNPs. In addition, we found that coating of 
ZNPs with ZBP-ScaA antigens can reduce negative sur-
face charge and particle agglomeration, especially in buff-
ered salt solution, which may also facilitate intracellular 
uptake of the ZNP-antigen complexes [32, 36].
Fig. 5 Production of type 1 (IFN‑γ and IL‑2) and type 2 (IL‑10) 
cytokines from splenocyte cultures in the absence (white bar) or 
presence (gray bar) of ScaA antigen. Splenocytes were collected from 
mice (n = 3/group) immunized twice with the indicated antigens at 2 
weeks after second immunization
Fig. 6 Increased survival of ZNP/ZBP‑ScaA immunized mice. Mice 
(n = 5/group) were immunized with ZNP, ZBP‑ScaA, ZNP/ScaA, ZNP/
ZBP‑ScaA, and Alum/ZBP‑ScaA three times at 2 weeks interval. One 
week after last immunization, mice were challenged with 100 × LD50 
of O. tsutsugamushi. Their survival was monitored until all the surviv‑
ing mice recovered from the disease. *p < 0.05; **p < 0.01
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Second, ZNP itself can exert immunomodulatory 
and/or inflammatory effects on APCs, thereby promot-
ing specific immune responses [37, 38]. ZNP has been 
shown to induce reactive oxygen species (ROSs), inflam-
matory cytokines and chemokines (IL-1β, IL-6, IL-12, 
TNF-α, CXCL-5, CXCL-9, and CXCL-10), and surface 
activation markers (MHCII, CD1d, CD11c, CD40, CD80, 
and CD86) in APCs. Induction of these innate immune 
responses may result from the direct recognition of ZNPs 
by Toll-like receptors (TLR4 or TLR6) [39, 40] or indi-
rectly by intracellular ROS generation resulting from 
disrupted cellular zinc homeostasis [37, 38]. Recently, a 
study reported that particulate ZNPs might contribute 
to systemic inflammation in a TLR4-dependent man-
ner when exposed to respiratory tracts [39]. Interest-
ingly, among several inorganic NPs (TiO2, TiO2-silica, 
single-walled carbon nanotubes, multi-walled carbon 
nanotubes, and ZNPs), ZNP had the most drastic immu-
nological effects, leading to high expression of IL-1β and 
CXCL-9 in APCs [41]. Considering that classical alum 
adjuvants have been shown to induce strong inflamma-
tory responses by activation of inflammasome resulting 
in secretion of IL-1β, and by the release of danger-asso-
ciated molecular patterns from the injured cells [42], the 
inflammatory and cytotoxic nature of ZNPs could be the 
basis of its capacity as an immuno-adjuvant. Previously, it 
was showed that peritoneal administration of OVA anti-
gen with ZNP could significantly enhance OVA-specific 
IgG1 and IgE responses in the serum when compared to 
those of OVA-only sensitized mice after boost immuni-
zation [18]. The enhanced antibody responses after boost 
immunization as well as proliferation of lymphocytes 
upon antigenic stimulation indicate that ZNPs have an 
adjuvant effect for the induction of adaptive immunity. 
They also claim that the adjuvant effect of ZNP drives 
OVA-specific immune responses toward a TH2 response, 
as measured by increased IgG1 and IgE responses and by 
secretion of IL-4 and IL-5 in immune splenocytes upon 
OVA stimulation [18]. In this study, we found that both 
IgG1 and IgG2C responses, representing TH2 and TH1 
responses respectively, against ScaA antigen are dra-
matically enhanced by subcutaneous immunization of 
ZNP complexed with ZBP-ScaA antigen when compared 
to those of the ScaA or ZNP/ScaA immunized groups 
(Fig.  4a), suggesting the stronger affinity of the associ-
ated antigen to ZNP may further enhance the adjuvant 
efficacy of ZNP towards both TH2 and TH1 responses. 
Increased IFN-γ-positive T cell responses as well as 
reduced IL-10 production upon antigenic stimulation 
also further support the idea that the ZNP/ZBP-ScaA 
complex is more potent in generating TH1 response than 
ZNP/ScaA (Figs.  4, 5). Finally, we observed that immu-
nization with the ZNP/ZBP-ScaA complex can provide 
significant protection of immunized mice from lethal 
challenges of O. tsutsugamushi, whereas ZNP/ScaA failed 
to do so (Fig.  5). Considering that both humoral and 
cell-mediated immune responses are required for effi-
cient protection against bacterial challenge [28], we can 
conclude that the level of antibody and T cell responses 
against ScaA induced by immunization with ZNP/ZBP-
ScaA were strong enough to protect the mice. Therefore, 
enhanced affinity of an antigen to ZNP can contribute to 
generating stronger adaptive immune responses when 
delivered together with ZNP.
Although the US Food and Drug Administration 
approved the use of ZNPs as food additives and sun-
screen ingredients, safety concerns regarding its in  vivo 
toxicity have persisted [38, 43]. Extensive studies on the 
in vivo toxicity of ZNPs have been performed in animal 
models after exposing ZNPs via skin, oral, and inhala-
tion routes, which may cause ZNP accumulation in vital 
organs such as liver, kidney, and lungs as well as systemic 
increase of Zn2+ levels [38, 44]. Administration of excess 
ZNPs, ranging up to hundreds of mg/kg, via those routes 
can induce transient toxicity and inflammation in the 
affected organs, potentially due to dissolution of ZNPs 
and generation of ROS, but the excess ZNPs are not 
retained and are eventually eliminated from the system 
[38, 44]. In a few studies on the systemic toxicity of ZNPs 
or ZnO-containing NPs after parenteral administration 
[16, 45], transient accumulation of NPs, as well as local 
inflammation, in several internal organs or injection site 
have been observed. However, administered NPs were 
gradually removed from the body and the animals did not 
develop any significant systemic inflammation nor any 
detectable morbidity [16, 45]. In this study, we also did 
not observe any significant change with respect to mor-
bidity, body weight, and food intake after subcutaneous 
injection of ZNPs. Therefore, ZNPs might be safe enough 
to be used as a vaccine adjuvant after parenteral admin-
istration, although prolonged monitoring is necessary to 
exclude the potential for long-term toxicity with repeated 
injection for boost immunization.
Conclusions
In summary, ZNPs possess good adjuvant potential as a 
vaccine carrier when combined with an antigen having 
a high affinity to ZNPs. The immuostimulatory effect of 
ZNP as well as particulation of soluble antigen through 
complex formation might contribute to efficient delivery 
into antigen-presenting cells and concurrently enhance 
antigen-specific adaptive immune responses. In addition, 
the large surface area of NPs may allow for a dose-sparing 
effect for the vaccine antigen. Indeed, ZNPs complexed 
with ZBP-ScaA antigen could induce strong antibody 
responses as well as protective immunity against lethal 
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challenges of O. tsutsugamushi. Therefore, application of 
ZNPs combined with a specific soluble antigen could be a 
promising strategy as a novel vaccine carrier system.
Methods
Synthesis of zinc oxide nanoparticles
ZNPs were synthesized using an ethanol solution con-
taining 50  mM of Zn(NO3) 6H2O and 12  mM of cetyl-
trimethylammonium bromide (CTAB). After stirring for 
1 h, an equivalent volume of a 0.1 M solution of NaOH in 
ethanol was injected. After dynamic stirring for 1 h again, 
the mixed solution was rinsed several times with ethanol 
using an ultrasonicator and a centrifuge. The resulting 
ZNPs were dispersed in ethanol.
Screening of zinc oxide‑binding peptides
Random eight-mer peptides were synthesized at a pep-
tide synthesis facility (Peptron). 100  μg of peptide was 
incubated with 1 mg of ZNPs for 1 h at room tempera-
ture. The peptide-ZNP complexes were then washed 
5 times with phosphate-buffered saline (PBS) and the 
bound peptides were resolved by 25% sodium dode-
cyl sulphate–polyacrylamide gel electrophoresis (SDS-
PAGE). Peptide sequences on the gel were determined by 
Edman sequencing by a Procise 494 automated protein 
sequencer (Applied Biosystems).
ZBP binding assay
To measure the relative affinity of ZBPs to ZNPs, pep-
tides labeled at their carboxyl terminals with fluorescein 
isothiocyanate (FITC) was used. Different concentrations 
of FITC-tagged 1×  or 3×  ZBPs were incubated with 
50  µg of ZNPs for 1  h at room temperature. ZBP-ZNP 
complexes were washed 5 times in PBS, resuspended 
in 100 µl of PBS, and then transferred to a 96 well black 
plate for fluorescence intensity measurement using 
Infinite®M200 PRO (Taken Switzerland). For ZBP-ScaA 
binding assay, purified 3×  ZBP-ScaA or ScaA proteins 
were incubated with ZNPs for 1 h at room temperature. 
The bound proteins on ZNPs were collected by centrifu-
gation and quantitated by Coomassie blue staining after 
SDS-PAGE.
Isothermal titration calorimetry
The affinity between a selected ZBP and ZNPs was deter-
mined by isothermal titration calorimetry (ITC). ITC was 
performed using a MicroCal VP-ITC Microcalorimeter 
with Origin software and VPViewer2000 (MicroCal Inc.). 
Titrations were performed by injecting 30 consecutive 
10 μl aliquots of ZBP peptide (0.2 mM) into the ITC cell 
(volume =  1.4301  ml) containing nanoparticles (1  μM). 
Titration experiments were performed at 25 °C to deter-
mine the binding constant of ZBPs to the nanoparticle. 
The ITC data were corrected for the heat of dilution of 
the titrant by subtracting mixing enthalpies for 10  μl 
injections of ZBPs into nanoparticle-free solution. Bind-
ing stoichiometry, enthalpy, entropy, and equilibrium 
association constants were determined by fitting the cor-
rected data to a bimolecular (One type of binding site) 
interaction model (Microcal Origin software version 7.0).
Measurement of colloidal properties of ZNP
Microstructure of the ZNP was analyzed by transmission 
electron microscopy (TEM, FEI Tecnai F20) operated at 
an accelerating voltage of 200  kV where samples were 
prepared on carbon coated copper mesh grids. From 
the TEM image, about 80 ZNPs were counted to get the 
size distribution followed by Gaussian fitting to estimate 
an average diameter. Optical property of the ZNPs dis-
persed in ethanol was determined by employing a photo-
luminescence spectrometer (PL, Shimadzu RF-5300 PC). 
Hydrodynamic diameters and surface charges of ZNPs, 
before and after surface modification, were monitored by 
dynamic light scattering (DLS) and zeta potential meas-
urements (Malvern Nano-ZS90). Samples for DLS and 
zeta potential measurements were prepared in deionized 
(DI) water or phosphate-buffered saline (PBS). Prior to 
measurements, 1–2 ml of the samples were filled in dis-
posable cells after gentle sonication.
Immunofluorescence assay
Immunofluorescence confocal microscopy was used to 
visualize O. tsutsugamushi [46] and ZNP/ZBP complexes 
taken up DC2.4 cells. L929 cells were cultured on 12-mm 
diameter glass coverslips in 24-well plates and inoculated 
with O. tsutsugamushi. Plates were spun at 500×g for 
5 min to synchronize bacterial contact with the host cell 
monolayers and then incubated at 37 °C for the indicated 
times. Intracellular bacteria were stained by differential 
immunofluorescence as previously described [28]. DC2.4 
cells taken up ZNP/ZBP or ZNP/ZBP-ScaA complexes 
were stained with LysoTracker Red DND-99 (Molecular 
probe) to examine the co-localization of the complexes 
with lysosomes. Cells were observed using an Olympus 
FV1000 laser confocal microscope (Olympus) and ana-
lyzed using the Fluoview software (Olympus).
Production of recombinant ScaA antigens
The ScaA88–3000 protein (GenBank accession no. 
AM494475.1) was purified from E. coli as described 
previously [28]. To produce recombinant ZBP-ScaA 
protein, annealed double-stranded DNA (5′- GATCC 
T T TCCGTATGATG G CG G CGATG CGT T TCCG 
TATGATGGCG GCGATGCGTTTCCGTATGATGGCG 
GCGATGCGG-3′, BamHI and EcoRI sites underlined) 
encoding 3×  ZBP (FPYDGGDAFPYDGGDAFPYDGG 
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DA) was cloned into the pET28a-ScaA plasmid [28] 
after digestion with BamHI and EcoRI. The recombi-
nant protein was also produced and purified from E. coli 
as described previously [28]. The purified proteins were 
treated with endotoxin removal columns (Pierce) before 
use. Endotoxin contamination of the purified recombi-
nant proteins was determined using QCI-1000® End-
Point Chromogenic Endotoxin Detection kit (Lonza) and 
less than 20 E.U./ml.
Preparation of Orientia tsutsugamushi
Orientia tsutsugamushi Boryong strain was purified 
using a modified Percoll gradient purification method 
[47]. Orientia tsutsugamushi was propagated in L929 
cells. At 3–4  days post-infection, infectivity was deter-
mined using an indirect immunofluorescence assay [28]. 
When an infection rate of  >90% was achieved, the cells 
were harvested by centrifugation at 6000×g for 20  min. 
The cell pellet was resuspended with Tris-sucrose (TS) 
buffer (33 mM Tris–Cl (pH 7.4) and 0.25 M sucrose) and 
homogenized using 100 strokes of a Polytron homoge-
nizer (Wheaton Inc.) followed by centrifugation at 200×g 
for 5 min. The supernatant was then mixed with 40% Per-
coll (Pharmacia Fine Chemicals) in TS buffer and cen-
trifuged at 25,000×g for 60 min. The bacterial band was 
collected and centrifuged at 77,000×g for 30  min. The 
bacterial pellet was washed 3 times in TS buffer, resus-
pended in Dulbecco’s Modified Eagle Medium (DMEM), 
and stored in liquid nitrogen until use. The infectiv-
ity titer of the inoculum was determined as previously 
described [47].
Flow cytometry analysis
Lymphocytes collected from the spleens of immunized 
mice were cultured for 18–20  h in RPMI 1640 medium 
(Gibco) supplemented with 10% heat-inactivated FBS, 
50  nM β-mercaptoenthanol, 100 units/ml penicillin/
streptomycin, 2 mM l-glutamine (Welgene), and 10 μg/
ml of purified ScaA in 24-well, flat-bottomed culture 
plates (5  ×  106 cells/well). After incubation, GolgiPlug 
(BD Biosciences) was added for 6  h. Lymphocytes were 
washed three times with ice-cold FACS buffer (PBS con-
taining 1% bovine serum albumin and 1  mM EDTA). 
Cells were blocked on ice for 30  min with ultra-block 
solution containing 10% rat sera, 10% hamster sera, 10% 
mouse sera (Sigma) and 10  μg/ml of 2.4G2 monoclo-
nal antibody (BD Pharmingen). Cells then stained with 
FITC-conjugated CD4 or PE.cy7-conjugated CD8 anti-
bodies (BD Pharmingen) for 30  min at 4  °C. After sur-
face CD4 or CD8 staining, cells were washed three times 
with ice-cold FACS buffer and subjected to intracellular 
cytokine staining using the Cytofix/Cytoperm kit accord-
ing to the manufacturer’s instructions (BD Biosciences). 
Intracellular interferon-γ (IFN-γ) was stained using an 
APC-conjugated anti-IFN-γ antibody (BD Pharmingen) 
for 30 min at 4 °C. The stained cells were analyzed with a 
FACS LSRII flow cytometer (BD Biosciences). Data were 
analyzed by FlowJo software version 8.8.6 (FlowJo).
Enzyme‑linked immunosorbent assay (ELISA)
To determine the titer of antibodies specific to ScaA in 
the sera of immunized mice, immunoassay plates (Nunc) 
were coated with 100  μl of purified antigen at a con-
centration of 1 μg/ml at 4  °C overnight. The plates were 
then blocked for 2 h at room temperature with PBS con-
taining 5% skim milk. 100  μl of serum samples serially 
diluted twofold were incubated for 2 h at room tempera-
ture. After washing with PBS containing 0.05% Tween20 
(PBST), horseradish peroxidase (HRP)-conjugated goat 
anti-mouse IgM, IgG1, or IgG2c  (Santa Cruz Biotech-
nology) was added and incubated for 2  h at room tem-
perature. Wells were washed with PBST and incubated 
with 3,3′,5,5′-tetramethylbenzidine (TMB) peroxidase 
substrate solution (KPL) for 7  min. The reactions were 
stopped by addition of 1  M phosphoric acid solution. 
Absorbances were measured at 450  nm using a micro-
plate reader (Beckman Coulter Inc.).
Cytokine analysis
A total 106 splenocytes collected from immunized mice 
was cultured in the absence or presence of 10  μg/ml of 
purified ScaA antigen for 24  h at 37  °C, and superna-
tant was analyzed for IFN-γ, IL-2, and IL-10 by ELISA 
(eBioscience).
Immunization of mice and challenges
Six to eight-week-old female C57BL/6 mice (Orient Bio 
Inc) were immunized (n  =  5/group) subcutaneously 
three times at 2 week intervals. 20  μg of ScaA or ZBP-
ScaA protein were incubated with 100  μg of ZNPs for 
1  h at room temperature before immunization. Control 
immunization was performed with ScaA alone or using 
2% Alhydrogel adjuvant (Invitrogen) at an adjuvant: pro-
tein solution volume ratio of 1:1 according to the manu-
facturer’s instruction. Blood samples were collected with 
retro-orbital puncture at 1 week after each injection and 
used to determine the serum antibody titer. One week 
after the final immunization, mice were challenged intra-
peritoneally with 10 × LD50 of O. tsutsugamushi Boryong 
strain. Mice survival was monitored for 1 month after 
bacterial challenge.
Statistical analysis
Data was analyzed using the Graph Pad Prism 5.01 soft-
ware (GraphPad Software) and SigmaPlot (Jandel). Sta-
tistical analysis was performed using the two-tailed 
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Student’s t test with 95% confidence interval or One-way 
ANOVA. Data are expressed as the mean  ±  standard 
deviation. Statistical analysis on survival rates were per-
formed using the Mantel-Cox Log Rank test. p value less 
than 0.05 was considered statistically significant.
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